ES2446416T3 - Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos - Google Patents
Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos Download PDFInfo
- Publication number
- ES2446416T3 ES2446416T3 ES06844992.5T ES06844992T ES2446416T3 ES 2446416 T3 ES2446416 T3 ES 2446416T3 ES 06844992 T ES06844992 T ES 06844992T ES 2446416 T3 ES2446416 T3 ES 2446416T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- dihydroquinolin
- hydroxy
- oxo
- carboxamido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 89
- 230000002401 inhibitory effect Effects 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title description 51
- 102000004079 Prolyl Hydroxylases Human genes 0.000 title description 17
- 108010043005 Prolyl Hydroxylases Proteins 0.000 title description 17
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title description 5
- -1 methoxy, ethoxy, propoxy, butoxy Chemical group 0.000 claims abstract description 67
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 239000012453 solvate Substances 0.000 claims abstract description 8
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims abstract description 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 6
- 125000001544 thienyl group Chemical class 0.000 claims abstract description 6
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims abstract description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims abstract description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 3
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 150000003557 thiazoles Chemical class 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 68
- 239000002253 acid Substances 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 125000005518 carboxamido group Chemical group 0.000 claims description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 230000033444 hydroxylation Effects 0.000 claims description 8
- 238000005805 hydroxylation reaction Methods 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000002903 Thalassemia Diseases 0.000 claims description 5
- 208000037849 arterial hypertension Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 238000002689 xenotransplantation Methods 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 108091005880 Hemoglobin F Proteins 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- WGKMZXQUTYWYEG-LURJTMIESA-N (2s)-2-[(4-hydroxy-1-methyl-7-nitro-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=C([N+]([O-])=O)C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 WGKMZXQUTYWYEG-LURJTMIESA-N 0.000 claims description 2
- RQBZCUYDLKPTLI-ZETCQYMHSA-N (2s)-2-[(4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound CN1C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1C=CC=C2OC RQBZCUYDLKPTLI-ZETCQYMHSA-N 0.000 claims description 2
- PDSBXCAGPDHXJW-ZETCQYMHSA-N (2s)-2-[(4-hydroxy-6-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound CN1C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=CC(OC)=CC=C21 PDSBXCAGPDHXJW-ZETCQYMHSA-N 0.000 claims description 2
- YSWVYBJIIYDZLZ-ZETCQYMHSA-N (2s)-2-[(4-hydroxy-8-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound OC1=C(C(=O)N[C@@H](C)C(O)=O)C(=O)N(C)C2=C1C=CC=C2OC YSWVYBJIIYDZLZ-ZETCQYMHSA-N 0.000 claims description 2
- VXTIXHBJPXETFK-LURJTMIESA-N (2s)-2-[(5-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1F VXTIXHBJPXETFK-LURJTMIESA-N 0.000 claims description 2
- GFAXJGZPBAPTEP-LURJTMIESA-N (2s)-2-[(7-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=C(Br)C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 GFAXJGZPBAPTEP-LURJTMIESA-N 0.000 claims description 2
- ISDXBEXXVXZCTD-LURJTMIESA-N (2s)-2-[(7-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=C(F)C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 ISDXBEXXVXZCTD-LURJTMIESA-N 0.000 claims description 2
- GJARJBFKTNAVOM-UHFFFAOYSA-N 2-[(1-ethyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(CC)C2=C1 GJARJBFKTNAVOM-UHFFFAOYSA-N 0.000 claims description 2
- BKTGJRHYWQCAAF-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-quinolin-5-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(C3=CC=C4N(C(C(C(=O)NCC(O)=O)=C(O)C4=C3)=O)C)=CC=CC2=N1 BKTGJRHYWQCAAF-UHFFFAOYSA-N 0.000 claims description 2
- ZXEBQZLMZHGLKH-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-7-piperidin-1-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1N1CCCCC1 ZXEBQZLMZHGLKH-UHFFFAOYSA-N 0.000 claims description 2
- CJNOOVPHDXMSKW-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-6-naphthalen-1-yl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(C3=CC=C4N(C(C(C(=O)NCC(O)=O)=C(O)C4=C3)=O)C)=CC=CC2=C1 CJNOOVPHDXMSKW-UHFFFAOYSA-N 0.000 claims description 2
- IRBZJXLHUVEVRV-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-6-naphthalen-2-yl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=CC2=CC(C3=CC=C4N(C(C(C(=O)NCC(O)=O)=C(O)C4=C3)=O)C)=CC=C21 IRBZJXLHUVEVRV-UHFFFAOYSA-N 0.000 claims description 2
- WIDLPHCZZIYDLI-UHFFFAOYSA-N 2-[(4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound CN1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=C1C=CC=C2OC WIDLPHCZZIYDLI-UHFFFAOYSA-N 0.000 claims description 2
- LNNUHMLJMSPTKU-UHFFFAOYSA-N 2-[(4-hydroxy-6-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound CN1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=CC(OC)=CC=C21 LNNUHMLJMSPTKU-UHFFFAOYSA-N 0.000 claims description 2
- XDZPUSDZXBWOFY-UHFFFAOYSA-N 2-[(4-hydroxy-8-methoxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1C=CC=C2OC XDZPUSDZXBWOFY-UHFFFAOYSA-N 0.000 claims description 2
- DPJVIFGBDKAJDQ-UHFFFAOYSA-N 2-[(5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 DPJVIFGBDKAJDQ-UHFFFAOYSA-N 0.000 claims description 2
- HRDFJJPDFDMWEY-UHFFFAOYSA-N 2-[(5-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC(F)=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 HRDFJJPDFDMWEY-UHFFFAOYSA-N 0.000 claims description 2
- GMRWBXRYKVSCBX-UHFFFAOYSA-N 2-[(6-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(Br)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 GMRWBXRYKVSCBX-UHFFFAOYSA-N 0.000 claims description 2
- YNLOPXZRGDOVFA-UHFFFAOYSA-N 2-[(6-cyano-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(C#N)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 YNLOPXZRGDOVFA-UHFFFAOYSA-N 0.000 claims description 2
- TVDMHSMWQLPNKU-UHFFFAOYSA-N 2-[(7-ethyl-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC(CC)=CC=C21 TVDMHSMWQLPNKU-UHFFFAOYSA-N 0.000 claims description 2
- KDTRRLPFOLSPLL-UHFFFAOYSA-N 2-[(7-ethynyl-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C#CC1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 KDTRRLPFOLSPLL-UHFFFAOYSA-N 0.000 claims description 2
- XOANHYHRCYFHML-UHFFFAOYSA-N 2-[(7-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound FC1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 XOANHYHRCYFHML-UHFFFAOYSA-N 0.000 claims description 2
- RVQVBSPIIGFLSV-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-6-(3-propan-2-ylphenyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound CC(C)C1=CC=CC(C=2C=C3C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C3=CC=2)=C1 RVQVBSPIIGFLSV-UHFFFAOYSA-N 0.000 claims description 2
- BEIVZPXLBHRSPK-UHFFFAOYSA-N 2-[[4-hydroxy-6-(1h-indol-5-yl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2NC=CC2=CC(C2=CC=C3N(C(C(C(=O)NCC(O)=O)=C(O)C3=C2)=O)C)=C1 BEIVZPXLBHRSPK-UHFFFAOYSA-N 0.000 claims description 2
- QQRAQHVFIBXTJX-UHFFFAOYSA-N 2-[[4-hydroxy-6-(2-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 QQRAQHVFIBXTJX-UHFFFAOYSA-N 0.000 claims description 2
- SDFOIOCUHPEWPX-UHFFFAOYSA-N 2-[[4-hydroxy-6-(3-hydroxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC(O)=C1 SDFOIOCUHPEWPX-UHFFFAOYSA-N 0.000 claims description 2
- MBYNMHVPDBIWLW-UHFFFAOYSA-N 2-[[4-hydroxy-6-(3-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound COC1=CC=CC(C=2C=C3C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C3=CC=2)=C1 MBYNMHVPDBIWLW-UHFFFAOYSA-N 0.000 claims description 2
- VWLAGDXVNAQMTK-UHFFFAOYSA-N 2-[[4-hydroxy-6-(4-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 VWLAGDXVNAQMTK-UHFFFAOYSA-N 0.000 claims description 2
- AZEYCUJNIMJHAQ-UHFFFAOYSA-N 2-[[4-hydroxy-7-(3-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound COC1=CC=CC(C=2C=C3N(C)C(=O)C(C(=O)NCC(O)=O)=C(O)C3=CC=2)=C1 AZEYCUJNIMJHAQ-UHFFFAOYSA-N 0.000 claims description 2
- SDGJRLZWULLZMN-UHFFFAOYSA-N 2-[[4-hydroxy-7-(4-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 SDGJRLZWULLZMN-UHFFFAOYSA-N 0.000 claims description 2
- ZVQCQWFLCBLVOJ-UHFFFAOYSA-N 2-[[6-(3-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC(Cl)=C1 ZVQCQWFLCBLVOJ-UHFFFAOYSA-N 0.000 claims description 2
- SRCSZNBJRWKWDX-UHFFFAOYSA-N 2-[[7-(3-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=CC(Cl)=C1 SRCSZNBJRWKWDX-UHFFFAOYSA-N 0.000 claims description 2
- IKKFMIIGCCGGDU-UHFFFAOYSA-N 2-[[7-(3-cyanophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=CC(C#N)=C1 IKKFMIIGCCGGDU-UHFFFAOYSA-N 0.000 claims description 2
- HDEFCEUMWRQXMC-UHFFFAOYSA-N 2-[[7-(4-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=C(Cl)C=C1 HDEFCEUMWRQXMC-UHFFFAOYSA-N 0.000 claims description 2
- 238000011316 allogeneic transplantation Methods 0.000 claims description 2
- DIPSWLHNGLUACG-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(N)=O)C(=O)N(C)C2=C1 DIPSWLHNGLUACG-UHFFFAOYSA-N 0.000 claims description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims 7
- HJRSTWRGACBMNH-LURJTMIESA-N (2s)-2-[[4-hydroxy-1-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carbonyl]amino]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 HJRSTWRGACBMNH-LURJTMIESA-N 0.000 claims 2
- YYZUXHYOMIAURD-GFCCVEGCSA-N (2r)-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@H](C(C)C)C(O)=O)=C(O)C2=C1 YYZUXHYOMIAURD-GFCCVEGCSA-N 0.000 claims 1
- DHRMXCZYTHDBIP-SSDOTTSWSA-N (2r)-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@H](C)C(O)=O)=C(O)C2=C1 DHRMXCZYTHDBIP-SSDOTTSWSA-N 0.000 claims 1
- HWYYYJVHNKRVCP-QMMMGPOBSA-N (2s)-2-[(4-hydroxy-1,5-dimethyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1C HWYYYJVHNKRVCP-QMMMGPOBSA-N 0.000 claims 1
- QTPWDKFAKGUSNR-QMMMGPOBSA-N (2s)-2-[(4-hydroxy-1,6-dimethyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound CC1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 QTPWDKFAKGUSNR-QMMMGPOBSA-N 0.000 claims 1
- QQYJVAIJQSEXRU-QMMMGPOBSA-N (2s)-2-[(4-hydroxy-1,7-dimethyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=C(C)C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 QQYJVAIJQSEXRU-QMMMGPOBSA-N 0.000 claims 1
- NHXTVFKTKSKDRE-QMMMGPOBSA-N (2s)-2-[(4-hydroxy-1,8-dimethyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC(C)=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 NHXTVFKTKSKDRE-QMMMGPOBSA-N 0.000 claims 1
- DGNICZUCUWQNAE-NSHDSACASA-N (2s)-2-[(4-hydroxy-1-methyl-2-oxo-6-phenylquinoline-3-carbonyl)amino]propanoic acid Chemical compound C=1C=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=CC=1C1=CC=CC=C1 DGNICZUCUWQNAE-NSHDSACASA-N 0.000 claims 1
- YYZUXHYOMIAURD-LBPRGKRZSA-N (2s)-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C(C)C)C(O)=O)=C(O)C2=C1 YYZUXHYOMIAURD-LBPRGKRZSA-N 0.000 claims 1
- GNDOMVYVGPMTKV-VIFPVBQESA-N (2s)-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]butanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](CC)C(O)=O)=C(O)C2=C1 GNDOMVYVGPMTKV-VIFPVBQESA-N 0.000 claims 1
- DHRMXCZYTHDBIP-ZETCQYMHSA-N (2s)-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 DHRMXCZYTHDBIP-ZETCQYMHSA-N 0.000 claims 1
- IVUOWPDHABXFMB-LURJTMIESA-N (2s)-2-[(4-hydroxy-6-iodo-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound IC1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 IVUOWPDHABXFMB-LURJTMIESA-N 0.000 claims 1
- LWQLUUAZKKESRI-LURJTMIESA-N (2s)-2-[(6-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound BrC1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 LWQLUUAZKKESRI-LURJTMIESA-N 0.000 claims 1
- FBJAIKDPOGBTPU-LURJTMIESA-N (2s)-2-[(6-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound FC1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1 FBJAIKDPOGBTPU-LURJTMIESA-N 0.000 claims 1
- BGRDLIKDCZYUEO-LURJTMIESA-N (2s)-2-[[4-hydroxy-1-methyl-2-oxo-5-(trifluoromethyl)quinoline-3-carbonyl]amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1C(F)(F)F BGRDLIKDCZYUEO-LURJTMIESA-N 0.000 claims 1
- PNDLNSZTPRSEOJ-UHFFFAOYSA-N 2-[(4-hydroxy-1,5-dimethyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound CN1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=C1C=CC=C2C PNDLNSZTPRSEOJ-UHFFFAOYSA-N 0.000 claims 1
- LOMMFBDBEIBPER-UHFFFAOYSA-N 2-[(4-hydroxy-1,6-dimethyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound CN1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=CC(C)=CC=C21 LOMMFBDBEIBPER-UHFFFAOYSA-N 0.000 claims 1
- OIDAJIOHKIGKKC-UHFFFAOYSA-N 2-[(4-hydroxy-1,7-dimethyl-2-oxo-6-phenylquinoline-3-carbonyl)amino]acetic acid Chemical compound CC1=CC=2N(C)C(=O)C(C(=O)NCC(O)=O)=C(O)C=2C=C1C1=CC=CC=C1 OIDAJIOHKIGKKC-UHFFFAOYSA-N 0.000 claims 1
- BDXVRSYBYNXEAK-UHFFFAOYSA-N 2-[(4-hydroxy-1,7-dimethyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC(C)=CC=C21 BDXVRSYBYNXEAK-UHFFFAOYSA-N 0.000 claims 1
- JTKWPGHFKHVGHP-UHFFFAOYSA-N 2-[(4-hydroxy-1,8-dimethyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1C=CC=C2C JTKWPGHFKHVGHP-UHFFFAOYSA-N 0.000 claims 1
- QWJDZLMCFCZUAH-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-phenylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1 QWJDZLMCFCZUAH-UHFFFAOYSA-N 0.000 claims 1
- UAYVCEKLKCHCBI-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-piperidin-1-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1N1CCCCC1 UAYVCEKLKCHCBI-UHFFFAOYSA-N 0.000 claims 1
- IDFUVRPDGRDPCU-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-pyridin-2-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=N1 IDFUVRPDGRDPCU-UHFFFAOYSA-N 0.000 claims 1
- ODZRGPDHXJIJLC-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-pyridin-3-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CN=C1 ODZRGPDHXJIJLC-UHFFFAOYSA-N 0.000 claims 1
- RMKIREXGAHDSMJ-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-pyridin-4-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=NC=C1 RMKIREXGAHDSMJ-UHFFFAOYSA-N 0.000 claims 1
- UBKHZSZEYCFPPJ-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-pyrimidin-2-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=NC=CC=N1 UBKHZSZEYCFPPJ-UHFFFAOYSA-N 0.000 claims 1
- NMCWQJKAAVEEND-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-thiophen-2-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CS1 NMCWQJKAAVEEND-UHFFFAOYSA-N 0.000 claims 1
- AQMAUVGFMSXBIA-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-7-phenylquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=CC=C1 AQMAUVGFMSXBIA-UHFFFAOYSA-N 0.000 claims 1
- CIEYHXMRPLAFGQ-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-7-thiophen-2-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=CS1 CIEYHXMRPLAFGQ-UHFFFAOYSA-N 0.000 claims 1
- IOVWVVJXNYAZHE-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-7-thiophen-3-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C=1C=CSC=1 IOVWVVJXNYAZHE-UHFFFAOYSA-N 0.000 claims 1
- IREGYLCBLKVNQE-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]-2-methylpropanoic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NC(C)(C)C(O)=O)C(=O)N(C)C2=C1 IREGYLCBLKVNQE-UHFFFAOYSA-N 0.000 claims 1
- UMQOTZCXVAMZNY-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 UMQOTZCXVAMZNY-UHFFFAOYSA-N 0.000 claims 1
- BLFWXXSWDRFNQD-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-6-morpholin-4-yl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1N1CCOCC1 BLFWXXSWDRFNQD-UHFFFAOYSA-N 0.000 claims 1
- XRABXEQPBLOUCZ-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-7-nitro-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound [O-][N+](=O)C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 XRABXEQPBLOUCZ-UHFFFAOYSA-N 0.000 claims 1
- YSQFBTLKRBQMFS-UHFFFAOYSA-N 2-[(4-hydroxy-6-iodo-1,7-dimethyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound CN1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=C1C=C(C)C(I)=C2 YSQFBTLKRBQMFS-UHFFFAOYSA-N 0.000 claims 1
- UIZQPFBGDWCNSA-UHFFFAOYSA-N 2-[(4-hydroxy-6-iodo-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(I)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 UIZQPFBGDWCNSA-UHFFFAOYSA-N 0.000 claims 1
- MSLMWNFYCYYSDQ-UHFFFAOYSA-N 2-[(6-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(Cl)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 MSLMWNFYCYYSDQ-UHFFFAOYSA-N 0.000 claims 1
- CNIHRYJVPKDRNB-UHFFFAOYSA-N 2-[(6-fluoro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(F)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 CNIHRYJVPKDRNB-UHFFFAOYSA-N 0.000 claims 1
- HGAGTLBOGDXJGA-UHFFFAOYSA-N 2-[(7-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound BrC1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 HGAGTLBOGDXJGA-UHFFFAOYSA-N 0.000 claims 1
- GQOBYAODONUIGR-UHFFFAOYSA-N 2-[(7-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound ClC1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 GQOBYAODONUIGR-UHFFFAOYSA-N 0.000 claims 1
- ZQIWQINXKHEJDK-UHFFFAOYSA-N 2-[(7-cyano-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound N#CC1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 ZQIWQINXKHEJDK-UHFFFAOYSA-N 0.000 claims 1
- ROORRYYCMXQXFU-HQVZTVAUSA-N 2-[[(3s)-3,4-dihydroxy-1-methyl-2-oxo-4h-quinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2N(C)C(=O)[C@@](O)(C(=O)NCC(O)=O)C(O)C2=C1 ROORRYYCMXQXFU-HQVZTVAUSA-N 0.000 claims 1
- LEJVQFYNLWFGEW-UHFFFAOYSA-N 2-[[4-hydroxy-1,7-dimethyl-6-(2-methylpyridin-3-yl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound CC1=CC=2N(C)C(=O)C(C(=O)NCC(O)=O)=C(O)C=2C=C1C1=CC=CN=C1C LEJVQFYNLWFGEW-UHFFFAOYSA-N 0.000 claims 1
- ACPDGXXICBKLAU-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-5-(trifluoromethyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(C(F)(F)F)=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 ACPDGXXICBKLAU-UHFFFAOYSA-N 0.000 claims 1
- FNDGTZCZXKTKFW-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-6-(4-phenoxyphenyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C(C=C1)=CC=C1OC1=CC=CC=C1 FNDGTZCZXKTKFW-UHFFFAOYSA-N 0.000 claims 1
- OQIVEXVBRAKKFL-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-7-(1h-pyrazol-4-yl)quinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C=1C=NNC=1 OQIVEXVBRAKKFL-UHFFFAOYSA-N 0.000 claims 1
- INBJVINUXPKYEX-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-7-(trifluoromethyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound FC(F)(F)C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 INBJVINUXPKYEX-UHFFFAOYSA-N 0.000 claims 1
- MRJKHROJRDQJAT-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-6-(2-methylpyridin-3-yl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound CC1=NC=CC=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 MRJKHROJRDQJAT-UHFFFAOYSA-N 0.000 claims 1
- XXNCNRUMPIAIDB-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-6-(3-methylthiophen-2-yl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CSC(C=2C=C3C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C3=CC=2)=C1C XXNCNRUMPIAIDB-UHFFFAOYSA-N 0.000 claims 1
- DRONGOLLFNMGEL-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-6-(6-methylpyridazin-3-yl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound N1=NC(C)=CC=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 DRONGOLLFNMGEL-UHFFFAOYSA-N 0.000 claims 1
- ODXYDUCLSFKDJF-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-7-(2-methylphenyl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 ODXYDUCLSFKDJF-UHFFFAOYSA-N 0.000 claims 1
- JZZCVHSPQVDAIL-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-7-(3-methylthiophen-2-yl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CSC(C=2C=C3N(C)C(=O)C(C(=O)NCC(O)=O)=C(O)C3=CC=2)=C1C JZZCVHSPQVDAIL-UHFFFAOYSA-N 0.000 claims 1
- NJJNQUZQGGHGCI-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-7-(4-methylphenyl)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 NJJNQUZQGGHGCI-UHFFFAOYSA-N 0.000 claims 1
- BXEYEZLAUQJRBN-UHFFFAOYSA-N 2-[[4-hydroxy-7-(2-methoxyphenyl)-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound COC1=CC=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 BXEYEZLAUQJRBN-UHFFFAOYSA-N 0.000 claims 1
- PVAUXUZCDUECDQ-UHFFFAOYSA-N 2-[[6-(1-benzofuran-2-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2OC(C3=CC=C4N(C(C(C(=O)NCC(O)=O)=C(O)C4=C3)=O)C)=CC2=C1 PVAUXUZCDUECDQ-UHFFFAOYSA-N 0.000 claims 1
- FDHSKTGRIFCKQH-UHFFFAOYSA-N 2-[[6-(1-benzothiophen-2-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2SC(C3=CC=C4N(C(C(C(=O)NCC(O)=O)=C(O)C4=C3)=O)C)=CC2=C1 FDHSKTGRIFCKQH-UHFFFAOYSA-N 0.000 claims 1
- DVBXIMJHGBENQY-UHFFFAOYSA-N 2-[[6-(2,4-dimethyl-1,3-thiazol-5-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound S1C(C)=NC(C)=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 DVBXIMJHGBENQY-UHFFFAOYSA-N 0.000 claims 1
- AOKCFRPADXZDRT-UHFFFAOYSA-N 2-[[6-(2-bromophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1Br AOKCFRPADXZDRT-UHFFFAOYSA-N 0.000 claims 1
- GQGFROMYHNFYQB-UHFFFAOYSA-N 2-[[6-(2-chloro-5-methylpyrimidin-4-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound CC1=CN=C(Cl)N=C1C1=CC=C(N(C)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 GQGFROMYHNFYQB-UHFFFAOYSA-N 0.000 claims 1
- IHAYYPODDQNBMT-UHFFFAOYSA-N 2-[[6-(2-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1Cl IHAYYPODDQNBMT-UHFFFAOYSA-N 0.000 claims 1
- VHTNKZDLZCJIOV-UHFFFAOYSA-N 2-[[6-(2-cyclohexylphenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1C1CCCCC1 VHTNKZDLZCJIOV-UHFFFAOYSA-N 0.000 claims 1
- KWKXKGIRAOUYIX-UHFFFAOYSA-N 2-[[6-(2-fluorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1F KWKXKGIRAOUYIX-UHFFFAOYSA-N 0.000 claims 1
- JRVYFAPRRLVJJS-UHFFFAOYSA-N 2-[[6-(2-formylphenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC=C1C=O JRVYFAPRRLVJJS-UHFFFAOYSA-N 0.000 claims 1
- FIJFYTZGRHQOAW-UHFFFAOYSA-N 2-[[6-(3-fluorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC(F)=C1 FIJFYTZGRHQOAW-UHFFFAOYSA-N 0.000 claims 1
- JISFVAIEVSTGIG-UHFFFAOYSA-N 2-[[6-(3-formylphenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=CC(C=O)=C1 JISFVAIEVSTGIG-UHFFFAOYSA-N 0.000 claims 1
- ZXMBQUAZTPNOIT-UHFFFAOYSA-N 2-[[6-(4-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=C(Cl)C=C1 ZXMBQUAZTPNOIT-UHFFFAOYSA-N 0.000 claims 1
- CJQHZSFISSJCAZ-UHFFFAOYSA-N 2-[[6-(4-fluorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=C(F)C=C1 CJQHZSFISSJCAZ-UHFFFAOYSA-N 0.000 claims 1
- RIYFOIJFRMVPIG-UHFFFAOYSA-N 2-[[6-(4-tert-butylphenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=C(C(C)(C)C)C=C1 RIYFOIJFRMVPIG-UHFFFAOYSA-N 0.000 claims 1
- FQEIBXUATSWBKS-UHFFFAOYSA-N 2-[[6-(6-chloropyridin-3-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC=C(Cl)N=C1 FQEIBXUATSWBKS-UHFFFAOYSA-N 0.000 claims 1
- QNDQYSVMBBNUIT-UHFFFAOYSA-N 2-[[6-(6-chloropyrimidin-4-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CC(Cl)=NC=N1 QNDQYSVMBBNUIT-UHFFFAOYSA-N 0.000 claims 1
- DNRVJXMSJXGOHL-UHFFFAOYSA-N 2-[[7-(2-chlorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=CC=C1Cl DNRVJXMSJXGOHL-UHFFFAOYSA-N 0.000 claims 1
- GVIHCWNMKWDFMY-UHFFFAOYSA-N 2-[[7-(3,5-dimethyl-1,2-oxazol-4-yl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound CC1=NOC(C)=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 GVIHCWNMKWDFMY-UHFFFAOYSA-N 0.000 claims 1
- BCNXXNDZSWLACE-UHFFFAOYSA-N 2-[[7-(3-chloro-4-methoxyphenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C(Cl)C(OC)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 BCNXXNDZSWLACE-UHFFFAOYSA-N 0.000 claims 1
- JQRUSJFIJOXIDO-UHFFFAOYSA-N 2-[[7-(4-cyanophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=C(C#N)C=C1 JQRUSJFIJOXIDO-UHFFFAOYSA-N 0.000 claims 1
- KQJNXZIMWUSAEI-UHFFFAOYSA-N 2-[[7-(4-fluorophenyl)-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1C1=CC=C(F)C=C1 KQJNXZIMWUSAEI-UHFFFAOYSA-N 0.000 claims 1
- WIISHBAJGAEJJZ-UHFFFAOYSA-N 3-(carboxymethylcarbamoyl)-4-hydroxy-1-methyl-2-oxoquinoline-7-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 WIISHBAJGAEJJZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 250
- 238000005160 1H NMR spectroscopy Methods 0.000 description 137
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- 239000007787 solid Substances 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 40
- 239000000243 solution Substances 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 229910001868 water Inorganic materials 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 18
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 15
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 235000019260 propionic acid Nutrition 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 235000019341 magnesium sulphate Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229910052693 Europium Inorganic materials 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010003751 Elongin Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 5
- 102000004662 Elongin Human genes 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- WVMBPWMAQDVZCM-UHFFFAOYSA-N N-methylanthranilic acid Chemical compound CNC1=CC=CC=C1C(O)=O WVMBPWMAQDVZCM-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 102100035070 von Hippel-Lindau disease tumor suppressor Human genes 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- FZESGZQCRIEWET-UHFFFAOYSA-N 6-iodo-1-methyl-3,1-benzoxazine-2,4-dione Chemical compound C1=C(I)C=C2C(=O)OC(=O)N(C)C2=C1 FZESGZQCRIEWET-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- NPSFEYVICGGCLT-UHFFFAOYSA-N 5-iodo-2-(methylamino)benzoic acid Chemical compound CNC1=CC=C(I)C=C1C(O)=O NPSFEYVICGGCLT-UHFFFAOYSA-N 0.000 description 2
- OLNOSMJGISVGGX-UHFFFAOYSA-N 7-bromo-1-methyl-3,1-benzoxazine-2,4-dione Chemical compound BrC1=CC=C2C(=O)OC(=O)N(C)C2=C1 OLNOSMJGISVGGX-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000006108 VHL Human genes 0.000 description 2
- 101150046474 Vhl gene Proteins 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000036570 collagen biosynthesis Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DLVHGGOPTXQVST-UHFFFAOYSA-N ethyl 4-hydroxy-6-iodo-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound IC1=CC=C2N(C)C(=O)C(C(=O)OCC)=C(O)C2=C1 DLVHGGOPTXQVST-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- SVCGKBPEILLZIC-UHFFFAOYSA-N methyl 1-methyl-2,4-dioxo-3,1-benzoxazine-7-carboxylate Chemical compound CN1C(=O)OC(=O)C=2C1=CC(C(=O)OC)=CC=2 SVCGKBPEILLZIC-UHFFFAOYSA-N 0.000 description 2
- OHVZKVCPDYPKPK-UHFFFAOYSA-N methyl 4-hydroxy-1-methyl-2-oxo-3-[(2-oxo-2-phenylmethoxyethyl)carbamoyl]quinoline-7-carboxylate Chemical compound O=C1N(C)C2=CC(C(=O)OC)=CC=C2C(O)=C1C(=O)NCC(=O)OCC1=CC=CC=C1 OHVZKVCPDYPKPK-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FQPLWTZPVFRVEY-UHFFFAOYSA-N tert-butyl 4-hydroxy-6-iodo-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=C(I)C=C2C(O)=C(C(=O)OC(C)(C)C)C(=O)N(C)C2=C1 FQPLWTZPVFRVEY-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PCZOZSATUTWXIC-UHFFFAOYSA-N tetraethylazanium;cyanide Chemical compound N#[C-].CC[N+](CC)(CC)CC PCZOZSATUTWXIC-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MZWBNLBAYRKYPJ-LURJTMIESA-N (2s)-2-[(5-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1Br MZWBNLBAYRKYPJ-LURJTMIESA-N 0.000 description 1
- FNCFCXPMVJTFFU-LURJTMIESA-N (2s)-2-[(5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)N[C@@H](C)C(O)=O)=C(O)C2=C1Cl FNCFCXPMVJTFFU-LURJTMIESA-N 0.000 description 1
- XCHVYJDDCCKIJN-QMMMGPOBSA-N (2s)-3-hydroxy-2-[(4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2C(O)=C(C(=O)N[C@@H](CO)C(O)=O)C(=O)N(C)C2=C1 XCHVYJDDCCKIJN-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WMKGGPCROCCUDY-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one Chemical compound C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WMKGGPCROCCUDY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- NQWVSJYRMLAQPU-UHFFFAOYSA-N 1-methyl-2-oxoquinoline-3-carbonyl chloride Chemical compound C1=CC=C2C=C(C(Cl)=O)C(=O)N(C)C2=C1 NQWVSJYRMLAQPU-UHFFFAOYSA-N 0.000 description 1
- LSXSNVAJTUIEHR-UHFFFAOYSA-N 2,4-dioxo-1h-3,1-benzoxazine-7-carboxylic acid Chemical compound N1C(=O)OC(=O)C=2C1=CC(C(=O)O)=CC=2 LSXSNVAJTUIEHR-UHFFFAOYSA-N 0.000 description 1
- BFIQUDKGBIXRDK-UHFFFAOYSA-N 2-[(1-methyl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C=C(C(=O)NCC(O)=O)C(=O)N(C)C2=C1 BFIQUDKGBIXRDK-UHFFFAOYSA-N 0.000 description 1
- PWAAPMKZVVYGIK-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-2-oxo-6-pyrimidin-5-ylquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=CN=CN=C1 PWAAPMKZVVYGIK-UHFFFAOYSA-N 0.000 description 1
- DKHSAIGHCUAFBM-UHFFFAOYSA-N 2-[(4-hydroxy-1-methyl-7-morpholin-4-yl-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=1N1CCOCC1 DKHSAIGHCUAFBM-UHFFFAOYSA-N 0.000 description 1
- YNKWNICXYCOXNY-UHFFFAOYSA-N 2-[(4-methoxy-2-oxo-1h-quinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(OC)=C(C(=O)NCC(O)=O)C(=O)NC2=C1 YNKWNICXYCOXNY-UHFFFAOYSA-N 0.000 description 1
- IMVRLWUKJJLLGJ-UHFFFAOYSA-N 2-[[4-hydroxy-1-methyl-2-oxo-6-(3-pyrrolidin-1-ylphenyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C(C=1)=CC=CC=1N1CCCC1 IMVRLWUKJJLLGJ-UHFFFAOYSA-N 0.000 description 1
- AEOWBBPFHYCWEO-UHFFFAOYSA-N 2-[[6-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(C)C2=CC=C1C1=NC=C(C(F)(F)F)C=C1Cl AEOWBBPFHYCWEO-UHFFFAOYSA-N 0.000 description 1
- SGLKDHJPRNZWOX-UHFFFAOYSA-N 2-[[7-[4-(dimethylamino)phenyl]-4-hydroxy-1-methyl-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(C(O)=C(C(=O)NCC(O)=O)C(=O)N2C)C2=C1 SGLKDHJPRNZWOX-UHFFFAOYSA-N 0.000 description 1
- SZCPTRGBOVXVCA-UHFFFAOYSA-N 2-amino-6-chlorobenzoic acid Chemical compound NC1=CC=CC(Cl)=C1C(O)=O SZCPTRGBOVXVCA-UHFFFAOYSA-N 0.000 description 1
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 1
- FECNVDHIIJYRIA-UHFFFAOYSA-N 2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)CCC(=O)C(O)=O FECNVDHIIJYRIA-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- NGGGZUAEOKRHMA-UHFFFAOYSA-M 3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoate Chemical compound CC(C)(C)OC(=O)CC([O-])=O NGGGZUAEOKRHMA-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- LOVFSAZRZIAUSS-UHFFFAOYSA-N 4-hydroxy-6-iodo-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=C(I)C=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 LOVFSAZRZIAUSS-UHFFFAOYSA-N 0.000 description 1
- KNFANQYEPLHEDP-UHFFFAOYSA-N 4-hydroxy-7-methoxycarbonyl-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound OC1=C(C(O)=O)C(=O)N(C)C2=CC(C(=O)OC)=CC=C21 KNFANQYEPLHEDP-UHFFFAOYSA-N 0.000 description 1
- BSFCVAYFJQLZEU-UHFFFAOYSA-N 5-bromo-2,4-dimethyl-1,3-thiazole Chemical compound CC1=NC(C)=C(Br)S1 BSFCVAYFJQLZEU-UHFFFAOYSA-N 0.000 description 1
- NIGOFAVNIBBNJV-UHFFFAOYSA-N 5-chloro-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=C1C=CC=C2Cl NIGOFAVNIBBNJV-UHFFFAOYSA-N 0.000 description 1
- DPPLNMPUIUGPAO-UHFFFAOYSA-N 6-bromo-1-methyl-3,1-benzoxazine-2,4-dione Chemical compound C1=C(Br)C=C2C(=O)OC(=O)N(C)C2=C1 DPPLNMPUIUGPAO-UHFFFAOYSA-N 0.000 description 1
- DXSMYDSFWCOSFM-UHFFFAOYSA-N 6-bromo-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=CC(Br)=CC=C21 DXSMYDSFWCOSFM-UHFFFAOYSA-N 0.000 description 1
- PDGHWWQDMPEMKS-UHFFFAOYSA-N 7-bromo-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C=2C1=CC(Br)=CC=2 PDGHWWQDMPEMKS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000702191 Escherichia virus P1 Species 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YRYOXRMDHALAFL-UHFFFAOYSA-N N-(3-oxohexanoyl)homoserine lactone Chemical compound CCCC(=O)CC(=O)NC1CCOC1=O YRYOXRMDHALAFL-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000053200 Von Hippel-Lindau Tumor Suppressor Human genes 0.000 description 1
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
- JSFGZPUFCTXDJY-UHFFFAOYSA-N [2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1N1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JSFGZPUFCTXDJY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- VLQHNAMRWPQWNK-UHFFFAOYSA-N benzyl 2-aminoacetate;hydron;chloride Chemical compound Cl.NCC(=O)OCC1=CC=CC=C1 VLQHNAMRWPQWNK-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RYFCSKVXWRJEOB-UHFFFAOYSA-N dibenzyl propanedioate Chemical compound C=1C=CC=CC=1COC(=O)CC(=O)OCC1=CC=CC=C1 RYFCSKVXWRJEOB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- WDEDNBRRSDKAKC-UHFFFAOYSA-N methyl 4-hydroxy-8-methoxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC(OC)=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1 WDEDNBRRSDKAKC-UHFFFAOYSA-N 0.000 description 1
- XWKZJTBXSQLOTP-UHFFFAOYSA-N methyl 7-bromo-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=C(Br)C=C2N(C)C(=O)C(C(=O)OC)=C(O)C2=C1 XWKZJTBXSQLOTP-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 1
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- OSWULUXZFOQIRU-UHFFFAOYSA-N tert-butyl 2-aminoacetate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CN OSWULUXZFOQIRU-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000014848 ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74857705P | 2005-12-09 | 2005-12-09 | |
| US748577P | 2005-12-09 | ||
| US78535806P | 2006-03-24 | 2006-03-24 | |
| US785358P | 2006-03-24 | ||
| PCT/US2006/046785 WO2007070359A2 (en) | 2005-12-09 | 2006-12-08 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2446416T3 true ES2446416T3 (es) | 2014-03-07 |
Family
ID=38163416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06844992.5T Active ES2446416T3 (es) | 2005-12-09 | 2006-12-08 | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7728130B2 (enExample) |
| EP (1) | EP1960363B1 (enExample) |
| JP (1) | JP5202327B2 (enExample) |
| AU (1) | AU2006326662B2 (enExample) |
| CA (1) | CA2634168C (enExample) |
| ES (1) | ES2446416T3 (enExample) |
| WO (1) | WO2007070359A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855510B2 (en) * | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| JP5202327B2 (ja) * | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| WO2008076425A1 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| AU2007334323B2 (en) * | 2006-12-18 | 2011-03-10 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| US7569726B2 (en) * | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
| EP2136810A4 (en) * | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| ES2442847T3 (es) * | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| AU2008248234B2 (en) * | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| AU2008248165B2 (en) | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| US20110039878A1 (en) * | 2007-11-02 | 2011-02-17 | Volkmar Guenzler-Pukall | Methods for reducing blood pressure |
| EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| WO2009134750A1 (en) | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| GB0809262D0 (en) * | 2008-05-21 | 2008-06-25 | Isis Innovation | Assay |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| EP2370422B1 (en) | 2008-11-14 | 2019-06-05 | Fibrogen, Inc. | Thiochromene derivatives as hif hydroxylase inhibitors |
| ES2548250T3 (es) * | 2009-02-10 | 2015-10-15 | Janssen Pharmaceutica, N.V. | Quinazolinonas como inhibidores de prolilhidroxilasa |
| AU2015249140C1 (en) * | 2009-02-10 | 2017-12-14 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| KR20120065311A (ko) | 2009-07-15 | 2012-06-20 | 씬산 강 | 저산소증 모방체인 화합물, 및 그의 조성물 및 용도 |
| CN102638983B (zh) | 2009-11-06 | 2014-11-26 | 阿尔皮奥治疗学股份有限公司 | 用于治疗结肠炎的组合物和方法 |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| EP2536709A4 (en) | 2010-02-17 | 2013-11-27 | Univ Cornell | PROLYL HYDROXYLASE HEMMER AND USE METHOD THEREFOR |
| JP5755741B2 (ja) | 2010-08-13 | 2015-07-29 | ヤンセン ファーマシューティカ エヌ.ベー. | プロリルヒドロキシラーゼインヒビタとしての4−アミノキナゾリン−2−イル−1−ピラゾール−4−カルボン酸化合物 |
| CA2809287C (en) * | 2010-08-27 | 2018-05-22 | Gruenenthal Gmbh | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| AR082734A1 (es) | 2010-08-27 | 2012-12-26 | Gruenenthal Gmbh | Quinolino-3-carboxamidas sustituidas como moduladores de kcnq2/3 |
| WO2012025237A1 (en) | 2010-08-27 | 2012-03-01 | Grünenthal GmbH | Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators |
| PT2609083E (pt) | 2010-08-27 | 2015-07-01 | Gruenenthal Gmbh | 2-oxi-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3 |
| EP2611780A1 (en) | 2010-09-01 | 2013-07-10 | Grünenthal GmbH | Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators |
| RU2013120556A (ru) | 2010-10-14 | 2014-11-20 | Иммунар Аб | 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| CA2837560C (en) | 2011-06-06 | 2017-02-14 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| KR102029951B1 (ko) | 2011-07-22 | 2019-11-08 | 베이징 베타 파머수티컬 컴퍼니 리미티드 | 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도 |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| BR112014003200A2 (pt) | 2011-08-11 | 2017-04-04 | Actelion Pharmaceuticals Ltd | derivados de quinazolina-2,4-diona |
| US8512586B2 (en) * | 2011-09-01 | 2013-08-20 | Tel Epion Inc. | Gas cluster ion beam etching process for achieving target etch process metrics for multiple materials |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| ES2818977T3 (es) | 2011-10-25 | 2021-04-14 | Janssen Pharmaceutica Nv | Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico |
| US20140309256A1 (en) * | 2011-11-09 | 2014-10-16 | Fibrogen, Inc. | Therapeutic Method |
| AU2013368843B2 (en) * | 2012-12-24 | 2016-02-25 | Zydus Lifesciences Limited | Novel quinolone derivatives |
| PE20160194A1 (es) | 2013-06-13 | 2016-04-20 | Akebia Therapeutics Inc | Composiciones y metodos para tratar anemia |
| TW201946625A (zh) | 2013-11-15 | 2019-12-16 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
| US10716783B2 (en) | 2013-12-12 | 2020-07-21 | Cornell University | Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom |
| EP3177593A1 (en) * | 2014-08-06 | 2017-06-14 | Novartis AG | Quinolone derivatives as antibacterials |
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| SG11201707994UA (en) | 2015-04-01 | 2017-10-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| US11001570B2 (en) | 2016-12-13 | 2021-05-11 | Boehringer Ingelheim International Gmbh | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| CN107739378A (zh) * | 2017-11-14 | 2018-02-27 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| AU2019265629B2 (en) | 2018-05-09 | 2024-09-12 | Akebia Therapeutics, Inc. | Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN115010662B (zh) * | 2021-03-05 | 2023-12-08 | 广东东阳光药业股份有限公司 | 喹啉酮类化合物的晶型及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4935392A (enExample) | 1972-08-02 | 1974-04-01 | ||
| JPS5417754B2 (enExample) * | 1972-12-15 | 1979-07-02 | ||
| CA1022544A (en) | 1972-12-21 | 1977-12-13 | Yukiyasu Murakami | Process of preparing a heterocyclic acyl group-substituted cephalosporin derivative |
| JPS587637B2 (ja) * | 1973-12-27 | 1983-02-10 | 住友化学工業株式会社 | シンキペニシリンノ セイホウ |
| AT328085B (de) | 1974-04-23 | 1976-03-10 | Sumitomo Chemical Co | Verfahren zur herstellung neuer penicilline |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US4468394A (en) * | 1981-04-02 | 1984-08-28 | Eisai Co., Ltd. | Cephalosporin compounds |
| US4404201A (en) * | 1981-11-13 | 1983-09-13 | Warner-Lambert Company | Cephalosporins |
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| US4382089A (en) * | 1982-03-02 | 1983-05-03 | Warner-Lambert Company | Antibacterial amide compounds, compositions thereof and methods of using them |
| US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
| SU1735288A1 (ru) | 1990-03-05 | 1992-05-23 | Харьковский государственный фармацевтический институт | Способ получени N-R-замещенных амидов 4-гидроксихинолон-2 карбоновой -3-кислоты |
| IL100917A0 (en) | 1991-02-16 | 1992-11-15 | Fisons Plc | Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them |
| DE4138820A1 (de) * | 1991-11-26 | 1993-05-27 | Basf Ag | Chinolin-3-carbonsaeureamide, deren herstellung und verwendung |
| US5502035A (en) * | 1993-08-06 | 1996-03-26 | Tap Holdings Inc. | N-terminus modified analogs of LHRH |
| JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
| US5485717A (en) * | 1994-06-29 | 1996-01-23 | Williams International Corporation | Multi-spool by-pass turbofan engine |
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| US5726605A (en) * | 1996-04-14 | 1998-03-10 | Northrop Grumman Corporation | Silicon carbide RF power module |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
| US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| GB9911047D0 (en) * | 1999-05-12 | 1999-07-14 | Isis Innovation | Assay method and means |
| TWI287004B (en) * | 2000-12-28 | 2007-09-21 | Shionogi & Co | A pyridone derivative having an affinity effect for cannabinoid 2 type receptor |
| EP1487472B1 (en) * | 2001-12-06 | 2019-06-26 | Fibrogen, Inc. | Treatment of ischemic or hypoxic conditions using heterocyclic carboxamides |
| US7019141B2 (en) | 2002-10-21 | 2006-03-28 | Irm Llc | Quinolones with anti-HIV activity |
| WO2004103974A1 (ja) * | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | 置換2-オキソキノリン化合物およびその医薬用途 |
| WO2004104000A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | トリサイクリック縮合環化合物およびその医薬用途 |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Gpr34受容体機能調節剤 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) * | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
-
2006
- 2006-12-08 JP JP2008544521A patent/JP5202327B2/ja not_active Expired - Fee Related
- 2006-12-08 US US11/635,683 patent/US7728130B2/en active Active
- 2006-12-08 AU AU2006326662A patent/AU2006326662B2/en not_active Ceased
- 2006-12-08 CA CA2634168A patent/CA2634168C/en not_active Expired - Fee Related
- 2006-12-08 WO PCT/US2006/046785 patent/WO2007070359A2/en not_active Ceased
- 2006-12-08 ES ES06844992.5T patent/ES2446416T3/es active Active
- 2006-12-08 EP EP06844992.5A patent/EP1960363B1/en active Active
-
2010
- 2010-02-10 US US12/703,716 patent/US8012968B2/en active Active
- 2010-02-10 US US12/703,496 patent/US8017626B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20100240610A1 (en) | 2010-09-23 |
| JP2009519249A (ja) | 2009-05-14 |
| US7728130B2 (en) | 2010-06-01 |
| US8012968B2 (en) | 2011-09-06 |
| CA2634168C (en) | 2013-04-23 |
| AU2006326662B2 (en) | 2011-07-28 |
| US20100184763A1 (en) | 2010-07-22 |
| EP1960363B1 (en) | 2014-01-22 |
| WO2007070359A2 (en) | 2007-06-21 |
| JP5202327B2 (ja) | 2013-06-05 |
| CA2634168A1 (en) | 2007-06-21 |
| WO2007070359A3 (en) | 2008-04-03 |
| US8017626B2 (en) | 2011-09-13 |
| AU2006326662A1 (en) | 2007-06-21 |
| US20070249605A1 (en) | 2007-10-25 |
| EP1960363A2 (en) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2446416T3 (es) | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos | |
| ES2442847T3 (es) | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa | |
| ES2393326T3 (es) | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos | |
| ES2389063T3 (es) | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa | |
| ES2446418T3 (es) | Derivados de indanona que inhiben la prolil hidroxilasa | |
| US8097620B2 (en) | Diazaquinolones that inhibit prolyl hydroxylase activity | |
| Das et al. | Multiprotein dynamic combinatorial chemistry: a strategy for the simultaneous discovery of subfamily‐selective inhibitors for nucleic acid demethylases FTO and ALKBH3 | |
| WO2023034813A1 (en) | An eif4a inhibitor with a novel mechanism of action | |
| ES2702524T3 (es) | Compuestos como miméticos de hipoxia, y composiciones, y usos de estos | |
| CN116135858B (zh) | 一种呋喃并吡啶酮类化合物及其应用 | |
| KR100696139B1 (ko) | 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법 | |
| JP7416558B2 (ja) | フタラジノン化合物およびこれらの用途 | |
| Chen et al. | Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-x L inhibitor are tolerated | |
| CN103724269B (zh) | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 | |
| AU2021301444A1 (en) | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | |
| EP4058448A1 (en) | Substituted hydantoinamides as adamts7 antagonists | |
| WO2024105420A2 (en) | Cyclic designer scaffolds for the covalent targeting of proteins via michael addition | |
| CN110862358A (zh) | 一种芳基取代噁二嗪酮类化合物及其制备方法和应用 | |
| KR100553593B1 (ko) | 히스톤 디아세틸라제 저해활성을 갖는 벤즈히드록시아미드유도체 및 그의 제조방법 | |
| AU2020428814B2 (en) | Amphoteric fluorescent substance capable of being attached to biomaterials | |
| JP2009514865A (ja) | 有糸分裂キネシン阻害剤 | |
| KR100555021B1 (ko) | 히스톤 디아세틸라제 저해활성을 갖는 퀴녹살린 유도체 및그의 제조방법 | |
| Tidestav | Chemical design, synthesis and biological evaluation of novel proteolysis targeting chimeras (PROTACs) for the degradation of NUDT5 | |
| TW202304884A (zh) | 經取代之吡咯甲醯胺、其製備方法及其作為激酶抑制劑之用途 | |
| Balsollier et al. | Discovery of two noN-UDP-mimic inhibitors of O-GlcNAc Transferase by using DNA encoded library as a screening tools. |